Literature DB >> 12907656

The role of transforming growth factor alpha in determining growth factor independence.

Rana A Awwad1, Natalia Sergina, Haisu Yang, Barry Ziober, James K V Willson, Elizabeth Zborowska, Lisa E Humphrey, Robert Fan, Tien C Ko, Michael G Brattain, Gillian M Howell.   

Abstract

Growth factor independence is a hallmark of malignancy that is attributed to the development of autocrine growth factor loops in cancer cells. However, growth factor-dependent normal cells also exhibit autocrine activity, thus raising the issue of how endogenously produced activity in cancer cells differs in a manner that leads to growth factor independence. We have examined this issue by comparing growth factor-independent HCT116 human colon carcinoma cells with a growth factor-dependent subcompartment of malignant cells designated HCT116b that was isolated from the same patient tumor. Therefore, the development of the growth factor-independent phenotype represents clonal progression within the tumor in vivo. The growth factor independence of HCT116 cells was shown to be dependent on autocrine transforming growth factor (TGF)-alpha activity, yet the isoparental HCT116b subcompartment showed similar levels of TGF-alpha expression as HCT116 when cells were in exponential growth. When both cell lines were growth arrested by nutrient deprivation, HCT116b cells required nutrient replenishment and growth factors for reinitiation of DNA synthesis, whereas HCT116 cells required only nutrient replenishment. In contrast to growth factor-dependent HCT116b cells, the HCT116 cells showed up-regulation of TGF-alpha expression during growth arrest as a result of enhanced transcription. This increased TGF-alpha expression in quiescent HCT116 cells was associated with constitutive epidermal growth factor receptor (EGFR) activation in the growth-arrested state, whereas growth-arrested HCT116b cells did not show EGFR activation. TGF-alpha antisense transfection of HCT116 cells showed that EGFR activation was due to increased TGF-alpha expression. Pretreatment of growth-arrested HCT116 cells with AG1478, a selective inhibitor of EGFR tyrosine kinase activity, blocked the reinitiation of DNA synthesis, demonstrating that growth factor independence was due to the increased TGF-alpha expression and EGFR activation of these cells in growth arrest relative to growth factor-dependent HCT116b cells. Importantly, the level of EGFR activation in growth-arrested HCT116 cells was only slightly higher than that of exponential cells, indicating that it was inappropriate EGFR activation in growth arrest rather than the amplitude of activation that generated growth factor independence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907656

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  From wavy hair to naked proteins: the role of transforming growth factor alpha in health and disease.

Authors:  Bhuminder Singh; Robert J Coffey
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

2.  Co-expression of EGF receptor, TGFalpha and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis.

Authors:  Marco Tampellini; Marina Longo; Susanna Cappia; Elisa Bacillo; Irene Alabiso; Marco Volante; Luigi Dogliotti; Mauro Papotti
Journal:  Virchows Arch       Date:  2007-01-30       Impact factor: 4.064

3.  TGF-alpha expression as a potential biomarker of risk within the normal-appearing colorectal mucosa of patients with and without incident sporadic adenoma.

Authors:  Carrie R Daniel; Roberd M Bostick; William Dana Flanders; Qi Long; Veronika Fedirko; Eduard Sidelnikov; March E Seabrook
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

4.  The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis.

Authors:  Maged W Helmy; Asser I Ghoneim; Mohamed A Katary; Rana K Elmahdy
Journal:  Mol Biol Rep       Date:  2020-02-22       Impact factor: 2.316

5.  Expression of transforming growth factor-alpha and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance.

Authors:  Jing Zhang; Wen-Liang Wang; Qing Li; Qing Qiao
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

6.  Transforming growth factor-β suppresses metastasis in a subset of human colon carcinoma cells.

Authors:  Neka A K Simms; Ashwani Rajput; Elizabeth A Sharratt; Melanie Ongchin; Carol A Teggart; Jing Wang; Michael G Brattain
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

7.  Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells.

Authors:  Masanori Nakashima; Seiji Adachi; Ichiro Yasuda; Takahiro Yamauchi; Junji Kawaguchi; Toshimasa Hanamatsu; Takashi Yoshioka; Yukio Okano; Yoshinobu Hirose; Osamu Kozawa; Hisataka Moriwaki
Journal:  Mol Cancer       Date:  2011-07-03       Impact factor: 27.401

8.  Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells.

Authors:  Kristin M Müller; Ingun H Tveteraas; Monica Aasrum; John Ødegård; Mona Dawood; Olav Dajani; Thoralf Christoffersen; Dagny L Sandnes
Journal:  BMC Cancer       Date:  2011-10-02       Impact factor: 4.430

9.  Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.

Authors:  Matthew V Myers; H Charles Manning; Robert J Coffey; Daniel C Liebler
Journal:  Mol Cell Proteomics       Date:  2011-12-05       Impact factor: 5.911

10.  Intra-tumoral heterogeneity in metastatic potential and survival signaling between iso-clonal HCT116 and HCT116b human colon carcinoma cell lines.

Authors:  Sanjib Chowdhury; Melanie Ongchin; Elizabeth Sharratt; Ivan Dominguez; Jing Wang; Michael G Brattain; Ashwani Rajput
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.